[BREAKING] Hemerion obtains the FDA clearance for its next US clinical trial


Pr Nicolas Reyns, neurosurgeon, co-founder of Hemerion

Intraoperative Visualization and the Connectome: Pr Reyns, Hemerion co-founder,  to present its experience with fluorophores and photoactive molecules

In December, Hemerion will sponsor a two-day virtual conference organized by the Society for Neuro-Oncology (SNO). Pr. Nicolas Reyns MD, PhD (University Hospital of Lille, France), co-founder of Hemerion, will participate in this conference to share our team’s experience and innovations with photoactive drugs used to enhance neurosurgery outcomes in patients.

The virtual conference chaired by Dr.  S. Brem, MD (University of Pennsylvania) and Dr. C. Hadjipanayis, MD, PhD (Mount Sinai Health System) will bring together prominent European and American neuro-surgeons and neuro-oncologists on December 6 and 7. It will focus on intraoperative visualization of brain tumors with fluorescence-based technologies. It will notably highlight the technologies that permit maximal, safe resection of brain tumors. The Conference will also focus on connectomics and white matter pathways – keys to better understand glioma invasion, neuroplasticity and functional outcomes.

Intraoperative visualization and connectome

Hemerion co-founder Nicolas Reyns will share his long experience in using fluorescence-guided surgery (FGS) for brain tumor resection as applied to glioblastoma. Pr N. Reyns is Head of the neurosurgery oncology dept of the University Hospital of Lille and the author of over 100 scientific papers

He will also present the promising results obtained within the frame of the Indygo clinical trial sponsored by the University Hospital of Lille. This trial was designed to assess the usability and the safety of the Hemerion technology, which is partly based on the association of a molecule used for fluorescence-guided surgery: 5-aminolevulinic acid (5-ALA).

The Hemerion technology combines the photoactive properties of 5-ALA with novel photodynamic technologies to selectively kill tumor cells wherever lights penetrate . The first application of the Hemerion technology targets glioblastoma, the most aggressive primary brain tumor, in addition to the current standard of care.